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Cationic arene ruthenium-based tetranuclear complexes comprising rectangular structures have been obtained from the
dinuclear arene ruthenium complexes [Ru2(arene)2(OO∩OO)2Cl2] (arene=  p-cymene, hexamethylbenzene; 
OO∩OO=2,5-dihydroxy-1,4-benzoquinonato, 2,5-dichloro-1,4-benzo-quinonato) by reaction with pyrazine or bipyridine 
linkers (N∩N=pyrazine, 4,40-bipyridine, 1,2-bis(4-pyridyl)ethylene) in methanol in the presence of AgO3SCF3, forming 
tetranuclear cations of general for-mula [Ru4(arene)4(N∩N)2(OO∩OO)2]4þ. All complexes were isolated in good yield as 
triflate salts and were characterized by NMR and IR spectroscopy and studied by cyclic voltammetry. The
cytotoxicities of the water-soluble compounds of the 4,40-bipyridine and 1,2-bis(4-pyridyl)ethylene series have been 
established using ovarian A2780 cancer cells. The large rectangles incorporating 1,2-bis(4-pyridyl)-ethylene linkers are
ca. 5 times more cytotoxic (IC50 e 6 μM) than the 4,40-bipyridine-containing cations (IC50 g 30 μM). Structural 
characterization by X-ray diffraction of two representative compounds, i.e., the triflate salts of
[Ru4(hexamethylbenzene)4(4,4
0-bipyridine)2(2,5-dihydroxy-1,4-benzoquinonato)2]
4þ and [Ru4(hexamethylbenzene)4(1,2-
bis(4-pyridyl)ethylene)2(2,5-dichloro-1,4-benzoquinonato)2]
4þ, re-veals differently sized cavities, different flexibilities, and 
different packing arrangements, suggesting a correlation between these structural properties and the observed
cytotoxicities.
Introduction
The self-assembly of transition metal complexes with
polydentate ligands to give discrete supramolecular assem-
blies has been studied by several groups. Notably, in the
1990s,1 Fujita pioneered, and others subsequently used,2 the
combination of 90 coordination building blocks and ditopic
linear ligands to form square and rectangular architectures.
A few years later, a related approach was used to generate
three-dimensional networks.3 So far, amultitude of two- and
three-dimensional supramolecular structures incorporating
square-planar transition metal ions have been synthesized.4
These molecular architectures are very versatile and have
been used to generate confined environments that encapsu-
late compounds,5 protect and stabilize an otherwise unstable
molecule,6 inhibit telomerase by stabilizing G-quadru-
plexes,7 recognize and trap specific guest molecules,8 or even
act as microreactors for specific reactions.9
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trigonal prisms, hexagonal prisms, and other supramole-
cular assemblies.16 In addition, arene ruthenium complexes
(arene=benzene, toluene, p-cymene, hexamethylbenzene)
have been shown to afford supramolecular assemblies with
diverse functionalities and properties.17 Our first entry in the
field of supramolecular assemblies of metallarectangles in-
corporating arene ruthenium complexes dates back to 1997.
The tetranuclear complex [Ru4(p-cymene)4(4,4
0-bipyri-
dine)2(oxalato)2]
4þ, a molecular rectangle in which four
arene ruthenium units (arene= p-cymene) are bridged by
two oxalato ligands and two bipyridine units, was synthe-
sized from the dinuclear complex [Ru2(p-cymene)2(oxalato)-
Cl2] and the bidentate ligand 4,4
0-bipyridine (N∩N) in the
presence of AgCF3SO3.
18
Ruthenium compounds are considered as promising antic-
ancer agents, and many compounds have been evaluated in
vitro and in vivo.19 Ru(III) compounds have recently entered
clinical trials,20 and arene ruthenium(II) complexes are at
a preclinical development stage.21 Compared to classical
platinum drugs, different affinities to biomolecules appear
to be of importance in the mode of action of ruthenium
compounds that potentially endows them with some advan-
tageous properties.22
Recently, a series of trinuclear p-cymene ruthenium
metallacycles connected with aminomethyl-substituted
3-hydroxy-2-pyridone ligands were evaluated in vitro against
cancer and fibroblast cell lines.23 It was postulated that the
water-soluble trinuclear complexes undergo fragmentation
after uptake, thus giving rise to cytotoxic mononuclear
complexes. We also reported the synthesis of water-soluble
metallaprisms that are able to encapsulate planar aro-
matic molecules (e.g., pyrene, coronene),24 or square-planar
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In the search for new building blocks for the synthesis of 
supramolecular boxes with comparable but modified prop-
erties, there has been an increasing interest in using transition 
metal complexes with octahedral geometry.10 Cotton and 
co-workers built up two- and three-dimensional structures 
from metal-metal paddlewheel units.11 Similarly, the fac-Re-
(CO)3 fragment was judiciously chosen to prepare molecular 
rectangles12 or triangular prisms.13 The tridentate ligand 
1,4,7-trithiacyclononane, which coordinates facially to ru-
thenium, has been used to form a supramolecular cube,14 
and polypyrazolyl chelating ligands coordinated to cobalt, 
manganese, and zinc ions can form various polyhedral 
cages.15 In a similar manner, cyclopentadienyl or arene 
ligands can be used to control the accessibility of coordina-
tion sites of an octahedral metal center. Thus, CpM and 
Cp*M (M=Rh, Ir; Cp=C5H5; Cp*=C5Me5) units have 
been extensively used to generate metallacycles, rectangles,
2
complexes (e.g., [Pd(acac)2], [Pt(acac)2]),
25 synthesized
from the dinuclear arene ruthenium complexes [Ru2-
(arene)2(OO∩OO)2Cl2] (arene=p-cymene, hexamethylben-
zene; OO∩OO = 2,5-dihydroxy-1,4-benzoquinonato, 2,
5-dichloro-1,4-benzoquinonato) and 2,4,6-tri(4-pyridyl)-
1,3,5-triazine (4-tpt). The “complex-in-a-complex” systems,
[M(acac)2⊂Ru6(p-cymene)6(4-tpt)2(2,5-dihydroxy-1,4-ben-
zoquinonato)3]
6þ (M=Pd, Pt), showed high cytotoxicity
toward human ovarian cancer cells.25
In this paper we describe the synthesis of some tetra-
nuclear metallarectangles of the general formula [Ru4-
(arene)4(N∩N)2(OO∩OO)2]4þ (arene = p-cymene, hexam-
ethylbenzene;OO∩OO=2,5-dihydroxy-1,4-benzoquinonato,
2,5-dichloro-1,4-benzoquinonato; N∩N= pyrazine, 4,40-bi-
pyridine, 1,2-bis(4-pyridyl)ethylene), prepared from the di-
nuclear arene ruthenium complexes 1-4;24,25 see Scheme 1.
The synthesis, characterization (including X-ray structure
analysis), and in vitro anticancer activity of these arene ruthe-
nium-based metallarectangles is reported together with their
electrochemical behavior.
Results and Discussion
The dinuclear arene ruthenium complexes [Ru2-
(arene)2(OO∩OO)Cl2] (1-4) react in methanol at room
temperature in the presence of silver triflate as a halide
scavenger with different N∩N donor ligands (N∩N=pyr-
azine, 4,40-bipyridine, 1,2-bis(4-pyridyl)ethylene) to give the
metallacyclic tetranuclear cations 5-16 stabilized as the
triflate salts (see Scheme 2). The chlorinated derivatives 6,
10, and 14 have also been synthesized by G.-X. Jin and
co-workers and reported recently.26 Compounds 1-4 and
[9-16][CF3SO3]4 are soluble in polar organic solvents such
as dichloromethane, acetone, methanol, or dimethylsulfox-
ide and also in water. On the other hand, compounds [5-8]-
[CF3SO3]4 dissolve only sparingly in acetone and dichloro-
methane and showrapiddecomposition indimethylsulfoxide.
The 1H NMR spectra of 5-8 display a singlet due to the
pyrazine protons. Unlike free pyrazine, where the proton
signal is found at δH=8.61 in acetone-d6, the signal in 5-8
appears slightly shifted downfield to δH=8.7 ppm. Upon
formation of the cationic tetranuclear metallarectangles, the
methyl and isopropyl signals of the p-cymene ligands in 5, 6,
9, 10, 13, and 14 remain almost unchanged as compared
to complexes 1 and 2, while the aromatic protons of the
p-cymene ligands are shifted downfield. On the other hand,
the proton signal of the 2,5-dihydroxy-1,4-benzoquinonato
bridging ligands in 5, 7, 9, 11, 13, and 15 is shifted upfield as
compared to the parent complexes 1 and 3. The infrared
spectra of 5-16 are dominated by absorptions of the
coordinated N∩N and OO∩OO ligands, which are only
slightly shifted as compared to the free ligands. In addition
to the N∩N and OO∩OO signals, strong absorptions due to
the triflate anions [1260(s), 1030(s), 638(m) cm-1] are also
observed in the infrared spectra of the salts [5-16][CF3SO3]4.
The single-crystal X-ray structure analysis of [11][CF3-
SO3]4 and [16][CF3SO3]4 confirms the expected rectangu-
lar structures. The molecular structures are presented in
Figures 1 and 2, respectively, along with selected geometrical
parameters.
Cations 11 and 16 contain four ruthenium metal centers
bonded to a hexamethylbenzene ligand,which are bridged by
the dianionicOO∩OO ligand through its four oxygen atoms
and linked by the neutral N∩N ligand. The Ru-N and
Ru-O distances observed in 11 and 16 are comparable to
those found in the hexacationic metallaprisms [guest⊂Ru6-
(arene)6(4-tpt)2(2,5-dihydroxy-1,4-benzoquinonato)3][CF3-
SO3]6 (guest=pyrene, benzo[e]pyrene, Pt(acetylacetonato)2,
hexamethoxytriphenylene).24,25,27 In 11 the 4,40-bipyridine
linkers show a twist of 4.6 between the two pyridyl units,
which is comparable to that found in other 4,40-bipyridine-
bridged ruthenium complexes.28
Scheme 1. Dinuclear Arene Ruthenium Complexes 1-4 2. Synthesis of the Metallarectangles 5-16
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Scheme
3
Interestingly, [11][CF3SO3]4 forms in the solid state one-
dimensional channels along the b axis with intramolecular
Ru-Ru separations of 7.9 and 11.3 A˚ (Figure 3). A similar
arrangement along the c axis has been found in the crystal
structure of [10][CF3SO3]4, with almost identical Ru-Ru
separations (7.9 and 11.2 A˚).26 In both structures the tri-
flate anions are located between the rectangular channels.
However, in [10][CF3SO3]4 disordered water molecules are
observed in the cationic molecular rectangle as compared to
[11][CF3SO3]4 forwhich no solventmolecules are observed in
the hydrophobic cavity. As expected, themolecular structure
of [16][CF3SO3]4 shows a larger cavity (7.9 13.6 A˚2). Upon
crystallization of [16][CF3SO3]4 from a chloroform/diethyl
ether mixture, two diethyl ether molecules are encompassed
in the hydrophobic cavity of cation 16 (Figure 3). A similar
crystal packing has been observed in [14][CF3SO3]4 in which
highly disordered solvent molecules were found in the
rectangular 7.9  13.5 A˚2 cavity.26
Compounds 1-4 and [9-16][CF3SO3]4 have been studied
by cyclic voltammetry at a platinum disk electrode. The
measurements were performed on ca. 0.5 mM (or saturated)
dichloromethane solutions containing 0.1MBu4NPF6 as the
supporting electrolyte. Pertinent data are summarized in
Table 1.
The redox response of the dinuclear complexes 1-4 is
roughly similar, the compounds displaying one or two well-
separated oxidations and one or two reductions in the
accessible potential range. Unfortunately, the reduction
waves are difficult to study, as they occur at the upper limit
of the potential window provided by the solvent.
Complex 1 shows two well-separated irreversible reduc-
tions at -1.20 and -1.89 V and an oxidation at around
þ1.0 V (Figure 4). Replacement of 2,5-dihydroxy-1,4-ben-
zoquinonato with 2,5-dichloro-1,4-benzoquinonato bridges
such as in 2 results in a shift of the reductive waves to less
negative potentials while making the single oxidation more
difficult (Table 1). In addition, the presence of the 2,5-
dichloro-1,4-benzoquinonato ligand renders the first reduc-
tion wave reversible (Figure 4). The wave is observed with
full electrochemical reversibility when recorded with the
switching potential set before the second reduction process
at scan rates down to 0.1V s-1.However, upon extending the
scan range further beyond the second reduction wave, the
anodic peak current due to the first wave becomes lower than
its corresponding cathodic counterpeak. This points to some
coupled chemical processes that consume the electrogener-
ated species and is in accordance with the fact that the second
reduction is accompanied by adsorption processes or decom-
position.
The replacement of the p-cymene ligand for hexamethyl-
benzene (1 f 3 and 2 f 4) leaves the redox pattern vir-
tually unchanged, but the respective waves appear shifted
to more negative potentials. Apparently, the higher donor
ability of the hexamethylbenzene ligand makes any electron
addition more difficult while facilitating the oxidative
processes. For 3, this “shift” allows for observation of
two oxidative waves at þ0.76 and ca. þ1.1 V, whereas
the expected second reduction falls outside the accessible
potential range.
In analogy to the previous reports dealing with electro-
chemistry of diruthenium complexes featuring 2,5-dihy-
droxy-1,4-benzoquinonato and 2,5-dichloro-1,4-benzoquin-
onato bridges,29,30 we can formally assign the cathodic pro-
cesses to one-electron reductions that occur predominantly
at the bridging ligand and attribute the oxidations to the
Ru(II)/Ru(III) couples. Nevertheless, this assignment is
only qualitative, particularly if one considers the exten-
sive mixing of the metal-based orbitals with those loca-
ted at the bridging ligands as established by theoretical
calculations.30a
Figure 1. ORTEP representation of cation 11 at 35% prob-
ability level with H atoms omitted for clarity. Selected bond
lengths (A˚) and angles (deg): Ru(1)-O(1) 2.086(3), Ru(2)-O(2)
2.089(3), Ru(1)-N(1) 2.109(4), Ru(2)-N(2) 2.109(4); N(1)-Ru-
(1)-O(1) 84.13(12), O(1)-Ru(1)-O(1)i 77.24(14), N(2)-Ru-
(2)-O(2) 84.56(12), O(2)-Ru(2)-O(2)i 77.18(14) (i= x, -y, z).
Figure 2. ORTEP representation of cation 16 at 35% prob-
ability level with H atoms omitted for clarity. Selected bond
lengths (A˚) and angles (deg): Ru(1)-N(1) 2.108(2), Ru(1)-O(1)
2.0927(18), Ru(1)-O(2) 2.0837(18), Ru(2)-N(2) 2.111(2), Ru-
(2)-O(3) 2.0965(18), Ru(2)-O(4) 2.0937(18); N(1)-Ru(1)-O-
(1) 86.53(8), N(1)-Ru(1)-O(2) 84.08(8), O(1)-Ru(1)-O(2)
77.12(7), N(2)-Ru(2)-O(3) 82.75(8), N(2)-Ru(2)-O(4) 86.27-
(8), O(3)-Ru(2)-O(4) 76.93(7).
(29) Kitagawa, S.; Kawata, S. Coord. Chem. Rev. 2002, 224, 11–34.
(30) (a) Ward, M. D. Inorg. Chem. 1996, 35, 1712–1714. (b) Gupta, A.
K.; Gupta, A.; Choudhury, A. Indian J. Chem. 2002, 41A, 2076–2078. For
osmium analogues, see: (c) Gupta, P.; Das, A.; Basuli, F.; Castineiras, A.;
Sheldrick, W. S.; Mayer-Figge, H.; Bhattacharya, S. Inorg. Chem. 2005, 44,
2081–2088. For iridium analogues, see: (d) Lin, Y.-J.; Jia, W.-G.; Jin, G.-X.
Organometallics 2008, 27, 4088–4097.
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Like in the case of the dinuclear compounds, the overall
redox response of the tetraruthenium complexes 9-16 is
analogous. Compared with their diruthenium precursors,
complexes 9-16 bear a high positive charge and, hence, are
more prone to reduction, whereas their oxidative waves are
either observed at the onset of the base electrolyte decom-
position (13) or not observed at all due to their highly
positive redox potentials.
The p-cymene ruthenium complex possessing 4,40-bipyr-
idine bridges, compound 9, undergoes first a reversible
reduction at-0.68 V followed by two successive irreversible
reductions at -1.39 and -1.90 V (Figure 5). The following
redox steps apparently influence the first one: When the
scanning is performed just over the first reduction, the first
reduction is observed with full electrochemical reversibility.
Upon increasing the switching potential so that the scan
involves the subsequent redox step(s), the oxidative peak
due to the first wave is observed with a significantly lower
peak current. This again points to some associated follow-
up associated processes that consume the electrogenerated
product(s).
The behavior of the analogous compound 13 featuring 1,2-
bis(4-pyridyl)ethylene linkers is practically identical, except
that all the waves are shifted to slightly more negative
potentials. By contrast, the change of the bridge for the
2,5-dichloro-1,4-benzoquinonato anion has a more pro-
nounced effect. The first two waves in 10 and 14 (Figure 5)
are observed shifted to more positive potentials, which is in
accordance with the electron-withdrawing nature of the
chloride substituents replacing two hydrogen atoms at the
OO∩OO bridging ligand. In addition, both waves bear clear
signs of electrochemical reversibility, the first wave being
observed with full reversibility when the switching potential
is set just after the first reduction. The following wave can
be described as quasi-reversible, showing a lower peak
current for the back scan peak (anodic) than for the for-
ward (cathodic) peak (ipc> ipa).Moreover, scanning further
beyond the second wave (i.e., toward more negative poten-
tials) markedly lowers the reversibility of the first redox step,
causing an increase in the separation of the counterpeaks and
lowering of the current of the respective anodic counterwave.
The redox behavior of 11-15 and 12-16 is complicated
by adsorption phenomena that become particularly pro-
nounced upon repeated scanning and reduce the reversibility
and reproducibility of the cyclic voltammograms. This is
particularly the case of 15, which shows additional ill-defined
reductive peaks and a strong stripping peak in the anodic
region.
The antiproliferative activity of the water-soluble com-
pounds containing the ligands 4,40-bipyridine (9-12) and
1,2-bis(4-pyridyl)ethylene (13-16) was evaluated against
the A2780 ovarian cancer cell line. All complexes exhibit
moderate to excellent activity with IC50 values in the range
4-66 μM (Table 2). In each case, the hexamethylbenzene
complexes exhibit lower IC50 values than their p-cymene
analogues, probably resulting from increased uptake due to
their greater lipophilicity. Similarly, complexes containing
the dihydroquinone linkers are generally more active than
the less lipophilic dichloroquinone analogues. There does
not appear to be a correlation between the redox potentials
of the compounds and their cytotoxicity, which is perhaps
not surprising since it is generally considered that Ru(III)
compounds are reduced to Ru(II) compounds31 inside the
reductive environment of a tumor (with Ru(0) not biologi-
cally accessible), and therefore the compounds investigated
herein are already in the active oxidation state.
Interestingly, the large rectangles incorporating 1,2-bis-
(4-pyridyl)ethylene and 2,5-dihydroxy-1,4-benzoquinonato
linkers (complexes 13 and 15) are up to an order of magni-
tude more cytotoxic (IC50 e 6 μM) than the 4,40-bipyridine-
containing cations (IC50g 30 μM). The reason for this effect
is not clear but it could be linked to the increased flexibility
of the 1,2-bis(4-pyridyl)ethylene linker that may allow the
rectangular structures to adapt their shape to better fit with
a molecular target. However, it cannot be ruled out that the
tetranuclear cations fragment once inside a cell and that the
fragments induce the cytotoxic effect.
In conclusion, a series of rectangular tetraruthenium tetra-
cationic complexes have been prepared and characterized
Figure 3. Capped sticks representations of 11 (left) and [(diethyl ether)2⊂16] (right).
Table 1. Summary of the Electrochemical Data of Complexes
1-4 and 9-16a
compound E [V]
1 -1.20 (ir.), -1.89 (ir.); ca. þ1.0 (ir.)
2 -0.90 (rev.), -1.76 (ir.),b ca. þ1.1 (ir.)
3 -1.37 (ir.), þ0.76 (ir.), ca. þ1.1 (ir.)
4 -1.06 (rev.), ca. -2.0 (ir.), ca. þ0.76 (ir.)
[9][CF3SO3]4 -0.68 (rev.),c -1.39 (ir.), -1.90 (ir.)
[10][CF3SO3]4 -0.45 (rev.),c -1.15 (rev.)c,d
[11][CF3SO3]4 -0.82 (rev.)c, ca. -1.6 (ir.)
[12][CF3SO3]4 -0.55 (rev.), -1.35 (rev.)c
[13][CF3SO3]4 -0.70 (rev.), -1.42 (ir.), ca. -1.9 (ir.)
[14][CF3SO3]4 -0.45 (rev.), -1.19 (rev.)c, ca. -1.9 (ir.)
[15][CF3SO3]4 -0.56 (rev.),c -1.44 (ir.)
[16][CF3SO3]4 -0.57 (rev.),c -1.41 (rev.)c, ca. -2.0 (ir.)
aPotentials are given relative to ferrocene/ferrocenium. Peak poten-
tials are quoted for irreversible (ir.) processes (Epa orEpc). The potentials
for reversible (rev.) couples are defined as the mean of the anodic and
cathodic peak potentials: E0 =1/2(Epa þ Epc). bA prepeak is observed
at -1.65 V. cSee text. dThe most negative peak is hidden by decom-
position of the base electrolyte and some decomposition processes.
(31) Clarke, M. J.; Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99,
2511–2533.
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by spectroscopic methods, X-ray diffraction, and cyclic
voltammetry. In addition, the water-soluble species were
screened for in vitro anticancer activity against the A2780
ovarian cancer cell line, and some of the compounds were
found to be highly active. It is likely that these large
rectangular complexes would be taken up more efficiently
by tumor cells,32 which are permeable to large, non-natural
molecules, whereas healthy cells are less able to take up such
structures, which should provide a degree of selectivity and
ultimately lead to reduced drug side effects.
Experimental Section
General Remarks. The dinuclear arene ruthenium complexes
[Ru2(arene)2(OO∩OO)Cl2] (arene = p-cymene, hexamethyl-
benzene; OO∩OO=2,5-dihydroxy-1,4-benzoquinonato, 2,5-
dichloro-1,4-benzoquinonato) (1-4) were prepared according
to published methods.24,25 All other reagents were commer-
cially available and used as received. The 1H and 13C{1H}
NMR spectra were recorded on a Bruker AMX 400 spectro-
meter using the residual protonated solvent as internal stan-
dard (acetone-d6: δH = 2.09 ppm). Infrared spectra were
recorded as KBr pellets on a Perkin-Elmer FTIR 1720-X
spectrometer. Microanalyses were performed by the Labora-
tory of Pharmaceutical Chemistry, University of Geneva
(Switzerland).
General Synthetic Method for [9-16][CF3SO3]4.Amixture of
1-4 (0.1 mmol) and 2 equiv of AgCF3SO3 (0.2 mmol) in
methanol (20 mL) is stirred at room temperature for 2 h and
then filtered to removeAgCl. To the red filtrate, the correspond-
ing N∩N ligand (0.1 mmol) is added. The mixture is stirred at
room temperature for 24 h, and the solvent is removed under
vacuum. The residue is taken up in dichloromethane (20 mL),
the extract is filtered and concentrated (3 mL), and diethyl ether
Figure 4. Cyclic voltammograms of 1 (left) and 2 (right) (0.5 mM in CH2Cl2 at Pt-disk, scan rate 0.1 V s
-1).
Figure 5. Cyclic voltammograms of 9 (left) and 14 (right) (0.5mM inCH2Cl2 at Pt-disk, scan rate 0.1V s
-1; first scan;, second scan ---).
Table 2. IC50 Values of Complexes 9-16 on A2780 Human
Ovarian Cancer Cells after 72 h Exposure
compound IC50 (μM)
[9][CF3SO3]4 66
[10][CF3SO3]4 43
[11][CF3SO3]4 27
[12][CF3SO3]4 33
[13][CF3SO3]4 6
[14][CF3SO3]4 29
[15][CF3SO3]4 4
[16][CF3SO3]4 23
cisplatin 2
(32) Modi, S.; Jain, J. P.; Domb, A. J.; Kumar, N. Curr. Pharm. Des.
2006, 12, 4785–4796.
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13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) 177.9 (CdO),
150.3 (CHpyz), 106.1 (Cp-cym), 104.5 (Cdbq), 98.8 (Cp-cym), 84.1
(CHp-cym), 83.9 (CHp-cym), 31.3 (CH(CH3)2), 21.4 (CH3), 17.3
(CH(CH3)2). IR (cm
-1): 1627(w), 1504(s), 1373(s), 1266(s),
1225(w), 1163(m), 1029(m), 637(m). Anal. Calcd for C64H64-
Cl4N4O20F12S4Ru4 3CH2Cl2: C, 35.54; H, 3.03; N, 2.55. Found:
C, 35.08; H, 3.17; N, 2.69.
[Ru4(hexamethylbenzene)4(pyrazine)2(2,5-dihydroxy-1,4-ben-
zoquinonato)2][CF3SO3]4 ([7][CF3SO3]4). Yield: 0.042 mmol
(83%). 1H NMR (400 MHz, acetone-d6): δ (ppm) 8.70 (s, 8H,
CHpyz), 5.72 (s, 4H, CHdbq), 2.20 (s, 72H, CH3).
13C{1H} NMR
(100 MHz, acetone-d6): δ (ppm) 183.9 (CdO), 148.0 (CHpyz),
101.7 (CHdbq), 93.7 (Chmb), 14.6 (CH3). IR (cm
-1): 1628(w),
1527(s), 1374(s), 1257(s), 1224(w), 1156(m), 1031(m), 638(m).
Anal. Calcd for C72H84N4O20F12S4Ru4 3CH2Cl2: C, 40.39; H,
3.99; N, 2.58. Found: C, 39.85; H, 4.01; N, 2.70.
[Ru4(hexamethylbenzene)4(pyrazine)2(2,5-dichloro-1,4-benzo-
quinonato)2][CF3SO3]4 ([8][CF3SO3]4). Yield: 0.037 mmol
(75%). 1H NMR (400 MHz, acetone-d6): δ (ppm) 8.71 (s, 8H,
CHpyz), 2.21 (s, 72H, CH3).
13C{1H} NMR (100MHz, acetone-
d6): δ (ppm) 183.8 (CdO), 148.0 (CHpyz), 105.3 (Cdbq), 93.7
(Chmb), 14.6 (CH3). IR (cm
-1): 1626(w), 1504(s), 1372(m), 1260
(m) 1158(w), 1031(m), 638(w). Anal. Calcd for C72H80Cl4-
N4O20F12S4Ru4: C, 38.89; H, 3.63; N, 2.52. Found: C, 38.63;
H, 3.77; N, 2.45.
[Ru4(p-cymene)4(4,4
0-bipyridine)2(2,5-dihydroxy-1,4-benzo-
quinonato)2][CF3SO3]4 ([9][CF3SO3]4). Yield: 0.037 mmol
(74%). 1H NMR (400 MHz, acetone-d6): δ (ppm) 8.54 (d, 8H,
3JH-H=4.4 Hz, CHbpy), 8.02 (d, 8H,
3JH-H=4.4 Hz, CHbpy),
6.20 (d, 8H, 3JH-H=8.0 Hz, CHp-cym), 5.99 (d, 8H,
3JH-H=
8.0 Hz, CHp-cym), 5.79 (s, 4H, CHdbq), 2.95 (sep, 4H,
3JH-H=
8.0 Hz, CH(CH3)2), 2.21 (s, 12H, CH3), 1.38 (d, 24H,
3JH-H=
8.0 Hz, CH(CH3)2).
13C{1H} NMR (100 MHz, acetone-d6): δ
(ppm) 174.3 (CdO), 154.0 (CHbpy), 144.7 (Cbpy), 123.6 (CHbpy),
103.7 (Cp-cym), 101.7 (CHdbq), 99.3 (Cp-cym), 83.9 (CHp-cym), 82.1
(CHp-cym), 31.2 (CH(CH3)2), 21.6 (CH3), 17.2 (CH(CH3)2). IR
(cm-1): 1637(s), 1616(s), 1526(m), 1378(s), 1259(m), 1159(s),
1030(s), 636(s). Anal. Calcd for C76H76N4O20F12S4Ru4: C,
42.94; H, 3.60; N, 2.64. Found: C, 42.91; H, 3.87; N, 2.61.
[Ru4(p-cymene)4(4,4
0-bipyridine)2(2,5-dichloro-1,4-benzoqui-
nonato)2][CF3SO3]4 ([10][CF3SO3]4). Yield: 0.038 mmol (75%).
1H NMR (400 MHz, acetone-d6): δ (ppm) 8.54 (d, 8H,
3JH-H=
6.4 Hz, CHbpy), 8.06 (d, 8H,
3JH-H=6.4 Hz, CHbpy), 6.28 (d,
8H, 3JH-H=6.4 Hz, CHp-cym), 6.11 (d, 8H,
3JH-H=6.4 Hz,
CHp-cym), 2.99 (sep, 4H,
3JH-H=6.8Hz, CH(CH3)2), 2.34 (s, 12H,
CH3), 1.42 (d, 24H,
3JH-H=6.8Hz, CH(CH3)2).
13C{1H}NMR
(100 MHz, acetone-d6): δ (ppm) 178.5 (CdO), 154.8 (CHbpy),
145.6 (Cbpy), 124.6 (CHbpy), 107.0 (Cp-cym), 104.8 (Cdbq), 100.1
(Cp-cym), 84.9 (CHp-cym), 83.8 (CHp-cym), 32.2 (CH(CH3)2), 22.5
(CH3), 18.2 (CH(CH3)2). IR (cm
-1): 1637(s), 1617(s) 1502(m)
1374(m), 1259(s), 1163(m), 1031(s) 638(s). Anal. Calcd for
C76H72N4O20F12S4Cl4Ru4: C, 40.32; H, 3.21; N, 2.47. Found:
C, 40.85; H, 3.32; N, 2.36.
[Ru4(hexamethylbenzene)4(4,4
0-bipyridine)2(2,5-dihydroxy-
1,4-benzoquinonato)2][CF3SO3]4 ([11][CF3SO3]4). Yield: 0.027
mmol (54%). 1H NMR (400 MHz, acetone-d6): δ (ppm) 8.39
(d, 8H, 3JH-H=5.3 Hz, CHbpy), 8.08 (d, 8H,
3JH-H=5.3 Hz,
CHbpy), 5.76 (s, 4H, CHdbq), 2.16 (s, 72H, CH3).
13C{1H} NMR
(100 MHz, acetone-d6): δ (ppm) 175.2 (CdO), 153.4 (CHbpy),
144.1 (Cbpy), 123.6 (CHbpy), 101.7 (CHdbq), 93.6 (Chmb), 14.7
(CH3). IR (cm
-1): 1638(s), 1617(s), 1525(s), 1375(m), 1258(s),
1162(m), 1032(s), 622(s). Anal. Calcd for C84H92N4O20F12S4-
Ru4: C, 45.08;H, 4.14;N, 2.50. Found:C, 45.01;H, 4.14;N, 2.32.
Crystals suitable for X-ray diffraction analysis were obtained
by slow diffusion of diethyl ether in an acetone solution of [11]-
[CF3SO3]4.
[Ru4(hexamethylbenzene)4(4,4
0-bipyridine)2(2,5-dichloro-1,4-
benzoquinonato)2][CF3SO3]4 ([12][CF3SO3]4). Yield: 0.036
mmol (73%). 1H NMR (400 MHz, acetone-d6): δ (ppm) 8.40
(dd, 8H, 3JH-H=5.4 Hz,
4JH-H=1.5 Hz, CHbpy), 8.13 (dd, 8H,
3JH-H=5.4Hz,
4JH-H=1.5Hz, CHbpy), 2.18 (s, 72H, CH3).
13C
{1H} NMR (100 MHz, acetone-d6): δ (ppm) 177.5 (CdO),
153.8 (CHbpy), 144.6 (Cbpy), 126.7 (CHbpy), 106.4 (Cdbq), 94.4
(Chmb), 15.2 (CH3). IR (cm
-1): 1637(s), 1617(s), 1499(s),
1369(m), 1259(s), 1161(m), 1032(s), 638(s). Anal. Calcd for
C84H88N4O20F12S4Cl4Ru4: C, 42.46; H, 3.73; N, 2.36. Found:
C, 42.44; H, 3.23; N, 2.32.
[Ru4(p-cymene)4{1,2-bis(4-pyridyl)ethylene}2(2,5-dihydroxy-
1,4-benzoquinonato)2][CF3SO3]4 ([13][CF3SO3]4). Yield: 0.040
mmol (80%). 1H NMR (400 MHz, acetone-d6): δ (ppm) 8.35
(d, 8H, 3JH-H=6.6 Hz, CHbpe), 7.74 (d, 8H,
3JH-H=6.6 Hz,
CHbpe), 7.63 (s, 4H,CHbpe), 6.17 (d, 8H,
3JH-H=6.4Hz,CHp-cym),
5.98 (d, 8H, 3JH-H=6.4 Hz, CHp-cym), 5.78 (s, 4H, CHdbq), 2.96
(sep, 4H, 3JH-H=7.1 Hz, CH(CH3)2), 2.23 (s, 12H, CH3), 1.36
(d, 24H, 3JH-H = 7.1 Hz, CH(CH3)2).
13C{1H} NMR
(100 MHz, acetone-d6): δ (ppm) 184.2 (CdO), 153.2 (CHbpe),
146.1 (Cbpe), 131.7 (CHbpe), 123.9 (CHbpe), 103.7 (Cp-cym), 101.7
(CHdbq), 99.0 (Cp-cym), 83.7 (CHp-cym), 82.1 (CHp-cym), 31.2 (CH
(CH3)2), 21.6 (CH3), 17.2 (CH(CH3)2). IR (cm
-1): 1638(s), 1616
(s), 1525(s), 1378(m), 1259(m), 1161(m), 1031(m), 636(s). Anal.
Calcd for C80H80N4O20F12S4Ru4: C, 44.12; H, 3.70; N, 2.57.
Found: C, 44.06; H, 3.86; N, 2.55.
[Ru4(p-cymene)4{1,2-bis(4-pyridyl)ethylene}2(2,5-dichloro-
1,4-benzoquinonato)2][CF3SO3]4 ([14][CF3SO3]4). Yield: 0.037
mmol (74%). 1H NMR (400 MHz, acetone-d6): δ (ppm) 8.32
(dd, 8H, 3JH-H=5.4 Hz,
4JH-H=1.4 Hz, CHbpe), 7.77 (dd, 8H,
3JH-H=5.4 Hz,
4JH-H=1.4 Hz, CHbpe), 7.69 (s, 4H, CHbpe),
6.25 (d, 8H, 3JH-H=6.4 Hz, CHp-cym), 6.08 (d, 8H,
3JH-H=6.4
Hz,CHp-cym), 3.03 (sep, 4H,
3JH-H=7.0Hz,CH(CH3)2), 2.32 (s,
12H, CH3), 1.42 (d, 24H,
3JH-H=7.0 Hz, CH(CH3)2).
13C{1H}
NMR (100 MHz, acetone-d6): δ (ppm) 178.0 (CdO), 153.3
(CHbpe), 146.4 (Cbpe), 132.0 (CHbpe), 124.2 (CHbpe), 106.2
(Cp-cym), 104.0 (Cdbq), 99.0 (Cp-cym), 83.9 (CHp-cym), 82.9
(CHp-cym), 31.4 (CH(CH3)2), 21.7 (CH3), 17.4 (CH(CH3)2). IR
(cm-1): 1638(s), 1619(s), 1501(s), 1373(m), 1258(s), 1163(m),
1031(m), 638(s). Anal. Calcd for C80H76N4O20F12S4Cl4Ru4: C,
41.49; H, 3.31; N, 2.42. Found: C, 41.43; H, 3.49; N, 2.26.
[Ru4(hexamethylbenzene)4{1,2-bis(4-pyridyl)ethylene}2(2,5-
dihydroxy-1,4-benzoquinonato)2][CF3SO3]4 ([15][CF3SO3]4).
Yield: 0.041 mmol (83%). 1H NMR (400 MHz, acetone-d6): δ
(ppm) 8.20 (dd, 8H, 3JH-H=5.4 Hz,
4JH-H=1.4 Hz, CHbpe),
7.76 (dd, 8H, 3JH-H=5.4 Hz,
4JH-H=1.4 Hz, CHbpe), 7.59 (s,
4H, CHbpe), 5.76 (s, 4H, CHdbq), 2.15 (s, 72H, CH3).
13C{1H}
NMR (100 MHz, acetone-d6): δ (ppm) 184.6 (CdO), 153.5
(CHbpe), 146.9 (Cbpe), 132.6 (CHbpe), 125.2 (CHbpe), 102.7
(CHdbq), 94.3 (Chmb), 15.6 (CH3). IR (cm
-1): 1638(s), 1617(s),
1524(m), 1374(m), 1257(m), 1112(m), 1031(m), 621(s). Anal.
Calcd for C88H96N4O20F12S4Ru4: C, 46.15; H, 4.22; N, 2.45.
Found: C, 46.32; H, 4.46; N, 2.29.
is slowly added to precipitate the product as a dark orange or red 
solid.
[Ru4(p-cymene)4(pyrazine)2(2,5-dihydroxy-1,4-benzoquino-
nato)2][CF3SO3]4 ([5][CF3SO3]4). Yield: 0.036 mmol (72%). 
1H 
NMR (400 MHz, acetone-d6): δ (ppm) 8.70 (s, 8H, CHpyz), 6.21 
(d, 8H, 3JH-H=6.4 Hz, CHp-cym), 6.05 (d, 8H, 
3JH-H=6.4 Hz, 
CHp-cym), 5.64 (s, 4H, CHdbq), 2.96 (sep, 4H, 
3JH-H=7.0 Hz, 
CH(CH3)2), 2.35 (s, 12H, CH3), 1.39 (d, 24H, 
3JH-H=7.0 Hz, 
CH(CH3)2). 
13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) 
184.8 (CdO), 149.9 (CHpyz), 104.8 (Cp-cym), 102.1 (CHdbq), 98.5 
(Cp-cym), 83.8 (CHp-cym), 83.2 (CHp-cym), 31.1 (CH(CH3)2), 21.1 
(CH3),16.5 (CH(CH3)2).IR (cm
-1): 1637(w), 1529(s), 1377(m), 
1259(s), 1227(w), 1162(m), 1030(m), 635(w). Anal. Calcd for 
C64H68N4O20F12S4Ru4: C, 38.95; H, 3.47; N, 2.84. Found: 
C, 38.73; H, 3.44; N, 2.78.
[Ru4(p-cymene)4(pyrazine)2(2,5-dichloro-1,4-benzoquino-
nato)2][CF3SO3]4 ([6][CF3SO3]4). Yield: 0.034 mmol (68%). 
1H 
NMR (400 MHz, acetone-d6): δ (ppm) 8.75 (s, 8H, CHpyz), 
6.30 (d, 8H, 3JH-H=6.4 Hz, CHp-cym), 6.14 (d, 8H, 
3JH-H=6.4 
Hz, CHp-cym), 3.06 (sep, 4H, 
3JH-H=6.9 Hz, CH(CH3)2), 2.44 
(s, 12H, CH3), 1.46 (d, 24H, 
3JH-H = 6.9 Hz, CH(CH3)2).
7
[Ru4(hexamethylbenzene)4{1,2-bis(4-pyridyl)ethylene}2(2,5-
dichloro-1,4-benzoquinonato)2][CF3SO3]4 ([16][CF3SO3]4).
Yield: 0.033 mmol (66%). 1H NMR (400 MHz, acetone-d6): δ
(ppm) 8.19 (dd, 8H, 3JH-H=6.6 Hz,
4JH-H=1.2 Hz, CHbpe),
7.80 (dd, 8H, 3JH-H=6.6 Hz,
4JH-H=1.2 Hz, CHbpe), 7.67 (s,
4H, CHbpe), 2.18 (s, 72H, CH3).
13C{1H} NMR (100 MHz,
acetone-d6): δ (ppm) 177.5 (CdO), 152.6 (CHbpe), 146.2 (Cbpe),
131.9 (CHbpe), 124.4 (CHbpe), 106.0 (Cdbq), 93.7 (Chmb), 14.7
(CH3). IR (cm
-1): 1638(s), 1617(s), 1498(s), 1370(m), 1164(m),
1031(m), 623(s). Anal. Calcd for C88H92N4O20F12S4Cl4Ru4: C,
43.53; H, 3.82; N, 2.31. Found: C, 43.92; H, 3.94; N, 2.25.
Crystals suitable for X-ray diffraction analysis were obtained
by slow diffusion of diethyl ether in an acetone solution of [16]-
[CF3SO3]4.
Electrochemistry. Electrochemical measurements were car-
ried out with a computer-controlled multipurpose potentiostat
μAUTOLAB III (Eco Chemie) at room temperature using a
standard Metrohm three-electrode cell with platinum disk
electrode (AUTOLAB RDE; 3 mm diameter) as the working
electrode, platinum sheet auxiliary electrode, and calomel re-
ference electrode (3 M KCl). The analyzed compounds were
dissolved in dichloromethane (Fluka, absolute, declared H2O
content e0.005%) to give a solution containing 5  10-4 M of
the analyte and 0.1MBu4NPF6 (Fluka, purissimum for electro-
chemistry). In the case of poorly soluble compounds, satura-
ted solutions were used. The solutions were deaerated with
argon prior to the measurement and then kept under an argon
blanket. The redox potentials are given relative to the ferrocene/
ferrocenium reference and are reproducible within ca. (5 mV.
Cytotoxicity Study.The humanA2780 ovarian cancer cell line
was obtained from the European Collection of Cell Cultures
(Salisbury, UK). Cells were grown routinely in RPMI medium
containing glucose, 5% fetal calf serum (FCS), and antibiotics
at 37 C and 5% CO2. Cytotoxicity was determined using the
MTT assay (MTT=3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide).33 Cells were seeded in 96-well plates
as monolayers with 100 μL of cell solution (approximately
20 000 cells) per well and preincubated for 24 h in medium
supplemented with 10% FCS. Compounds were predissolved
in DMSO, then added to the culture medium (to give a final
DMSO concentration of 0.5%) and serially diluted to the
appropriate concentration; 100 μL of drug solution was added
to each well, and the plates were incubated for another 72 h.
Subsequently, MTT (5 mg/mL solution) was added to the cells,
and the plates were incubated for a further 2 h. The culture
mediumwas aspirated, and the purple formazan crystals formed
by the mitochondrial dehydrogenase activity of vital cells were
dissolved in DMSO. The optical density, directly proportional
to the number of surviving cells, was quantified at 540 nm using
a multiwell plate reader, and the fraction of surviving cells
was calculated from the absorbance of untreated control
cells. Evaluation is based on means from two independent
experiments, each comprising 3microcultures per concentration
level.
X-ray Crystallographic Study. Crystals of [11][CF3SO3]4 and
[16][CF3SO3]4 3 (C4H10O)2 3 (C3H6O)2 were mounted on a Stoe
Image Plate Diffraction system equipped with a φ circle goni-
ometer, using Mo KR graphite-monochromated radiation
(λ=0.71073 A˚) with φ range 0-200, increment of 1.2 and
1.0, respectively, 2θ range from 4.0 to 52, Dmax - Dmin=
12.45-0.81 A˚. The structures were solved by direct methods
using the program SHELXS-97.34 Refinement and all further
calculations were carried out using SHELXL-97.34 Examina-
tion of the structures with PLATON35 reveals in [11][CF3SO3]4
voids between the anions and cations. Therefore, a new data set
corresponding to omission of the missing solvent and anions
was generated with the SQUEEZE algorithm,36 and the struc-
ture was refined to convergence. Otherwise, in both structures,
the H atoms were included in calculated positions and treated as
riding atoms using the SHELXL default parameters, and the
non H atoms were refined anisotropically, using weighted full-
matrix least-squares on F2. Crystallographic details are sum-
marized in Table 3. Figures 1 and 2 are drawn with ORTEP,37
while Figure 3 is drawn with MERCURY.38
CCDC-721012 [11][CF3SO3]4 and 721013 [16][CF3SO3]4 3
(C4H10O)2 3 (C3H6O)2 contain the supplementary crystallo-
graphic data for this paper. These data can be obtained free of
charge at www.ccdc.cam.ac.uk/conts/retrieving.html [or from
the Cambridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK; fax: (internat.) þ44-1223/336-033;
E-mail: deposit@ccdc.cam.ac.uk].
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[11][CF3SO3]4 [16][CF3SO3]4 3 solvent
chemical formula C102H124Cl4F12-
N4O24Ru4S4
C84H92F12N4-
O20Ru4S4
fw 2692.37 2238.14
cryst syst triclinic monoclinic
space group P1 (no. 2) P2/m (no. 10)
cryst color
and shape
orange block red block
cryst size 0.13  0.10  0.08 0.14  0.12  0.10
a (A˚) 13.9532(7) 15.2127(11)
b (A˚) 15.4561(8) 9.9525(5)
c (A˚) 15.8403(9) 20.6506(14)
R (deg) 66.311(4) 90
β (deg) 64.864(4) 109.011(5)
γ (deg) 76.075(4) 90
V (A˚3) 2822.0(3) 2956.1(3)
Z 1 1
T (K) 173(2) 173(2)
Dc (g 3 cm
-3) 1.584 1.257
μ (mm-1) 0.784 0.645
scan range (deg) 2.88 < 2θ< 51.28 2.84 < 2θ< 50.32
unique reflns 10 619 5565
reflns used
[I> 2σ(I)]
9210 4146
Rint 0.0438 0.0773
final R indices
[I> 2σ(I)]a
R1 0.0319,
wR2 0.0815
R1 0.0450,
wR2 0.1251
R indices
(all data)
R1 0.0381,
wR2 0.0839
R1 0.0596,
wR2 0.1309
goodness-of-fit 1.019 0.981
max., min.
ΔF (e A˚-3)
0.619, -0.608 0.478, -0.686
a Structures were refined on Fo
2: wR2 = [
P
[w(Fo
2 - Fc2)2]/
P
w(Fo
2)2]1/2,
where w-1 = [
P
(Fo
2) þ (aP)2 þ bP] and P= [max(Fo2, 0) þ 2Fc2]/3.
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Table 3. Crystallographic and Structure Refinement Parameters
for Compounds [11][CF3SO3]4 and [16][CF3SO3]4 3 (C4H10O)2 3 
(C3H6O)2
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